Compare Crispr Therapeutics AG (CRSP) vs LYFT Inc (LYFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs LYFT Inc — how do they compare? Crispr Therapeutics AG trades at $54.08 (market cap $5.17B), while LYFT Inc trades at $17.48 (market cap $6.53B). The key difference: LYFT Inc is the larger of the two by market cap, and LYFT Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | LYFT | |
|---|---|---|
Market Cap | $5.17B | $6.53B |
Sector | Health | Industrials |
52-Week High | $76.78 | $24.57 |
52-Week Low | $44.34 | $12.65 |
Enterprise Value | $3.59B | $6.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.52, up 3.64% in the last session, with a bullish technical outlook from moving averages but overbought RSI signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by Casgevy sales. Analyst consensus is a Buy with a $76 price target, reflecting optimism for pipeline catalysts.
The outlook is supported by strong product sales and clinical progress, but significant risks include persistent negative margins, high cash burn, and reliance on pipeline success. Investors face a high-risk, high-reward scenario with the stock trading near resistance levels amid volatile earnings history.
Lyft trades at $17.46, up 7.12% in the past 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong revenue growth to $6.32 billion in 2025 and a net income of $2.84 billion, though recent Q2 2026 earnings missed estimates. Positive cash flow trends and record active riders above 30 million signal operational strength, while an ongoing legal investigation presents a headwind.
The outlook is mixed: valuation ratios like P/E of 2.54 appear attractive, and analyst consensus targets $19.17, but earnings misses and competitive pressures weigh on sentiment. Key risks include fiduciary duty investigations and moderating booking growth, requiring careful monitoring of execution against guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →
